Eli Lilly and Company’s ambitions for mirikizumab to compete with AbbVie Inc.’s Skyrizi (risankizumab) in the inflammatory bowel disease space appear to be progressing with the recent re-filing of a biologic licensing application for ulcerative colitis and Phase III data reported on 12 October that shows Lilly’s IL-23 antagonist meeting statistical significance for both clinical remission and endoscopic response in Crohn’s disease.
Lilly Plans Mirikizumab Filing For Crohn’s After Phase III Success
Mirikizumab, already under review at the FDA for ulcerative colitis, bests placebo on two primary endpoints in Crohn’s. Lilly hopes to beat AbbVie’s Skyrizi, already approved for Crohn's, to market in UC.
More from Clinical Trials
• By
Aldeyra’s dry eye candidate reproxalap received a second FDA complete response letter, but the firm expressed confidence about refiling quickly based on two ongoing studies.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
More from R&D
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.